SparingVision Participated in the 10th Annual Biotech Showcase

PARIS, Jan. 12, 2018 -- SparingVision, a biotechnology company focused on the discovery and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa, announced today that Florence Allouche Ghrenassia, President and Chief Executive Officer, provided a corporate overview on January 10, 2018 at the 10^th Annual Biotech Showcase, held from January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California.

SparingVision was one of five private, French biotech companies selected out of nearly 250 companies to present at Biotech Showcase.

About SparingVision
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing a drug candidate to treat retinitis pigmentosa, the most frequent inherited retinal degeneration. There is no cure for this genetic condition, which can progress to blindness, and affects 2 million patients worldwide. SparingVision is a spin-off of Vision Institute (Institut de la Vision, Paris) and is the Grand Prize winner of the i-LAB 2017 French National Competition for Innovative Companies. It is one of the seven companies in the new Bpifrance accelerator for biotech companies, Hub Health Tech.

Contacts:
Florence Allouche Ghrenassia, Pharm D.     Linda Dyson, MPH
President and CEO                                       Executive Vice President
SparingVision                                                LifeSci Public Relations
Phone: +33 6 51 28 11 39                             Phone: 973.986.5973                              
[email protected]                                 Email: [email protected]